Dr. Robert Svatek was born and raised in Wharton, a small town approximately 60 miles southwest of Houston in the gulf coast region of Texas. He attended the University of Texas at Austin for undergraduate training and the University of Texas Medical Branch in Galveston for medical school. He then completed his urology residency training at the University of Texas Southwestern Medical Center in Dallas. Following residency, he completed a 3 year fellowship in urologic oncology at the University of Texas M.D. Anderson Cancer Center in Houston. While there, he also earned his master of science in clinical research investigation at the University of Texas Health Science Center at Houston, Center for Clinical Research and Evidence-Based Medicine. He was then recruited to the department of urology at the UT Health Science Center San Antonio in 2010, to build a bladder cancer center of excellence.
Dr. Svatek is recognized nationally as an expert in the management of superficial and advanced bladder cancer. Treatment of superficial bladder cancer requires careful, meticulous detail and adherence to surveillance regimens. It requires diligence in administration of proper standardized therapy, but treatment regimens must also be individualized. Expertise in the management of advanced bladder cancer requires proper timing and coordination of multiple treatment modalities available to treat the disease including surgery, radiation therapy and chemotherapy. Thus, Dr. Svatek works closely with other subspecialists to provide the optimal therapy for patients.
Dr. Svatek is one of the top five highest-volume bladder cancer surgeons in the United States, performing over 60 bladder removal procedures (cystectomies) yearly. He provides state-of-the-art surgical options, including robotic-assisted and open approaches, as well as all available urinary diversion options, including ileal conduit and continent diversions (Indiana pouch and neobladder). Dr. Svatek has developed a collaborative care pathway here in San Antonio with exceptional precision in the pre-operative and post-operative management of patients. Dr. Svatek aims to provide the people of south and southwest Texas with the highest level of expertise and compassionate care.
Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, Lotan Y. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. BJU Int. 2015 Oct 5. doi: 10.1111/bju.13345. [Epub ahead of print], PMID: 26435378
Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, Ankerst DP, Liss MA. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. Eur Urol. 2016 Mar;69(3):407-10. doi: 10.1016/j.eururo.2015.08.029. Epub 2015 Aug 28. PMID: 26320383
Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F, Dinney CP. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. Eur Urol. 2016 Feb;69(2):197-200. doi: 10.1016/j.eururo.2015.06.023. Epub 2015 Jun 25. PMID: 26119560